Lucis, an AI-powered personalized health guidance companion app, raised $20 million in a Series A round, led by Singular, with participation from General Catalyst, Y Combinator, and angels including investors behind Runna, Céline Lazorthes (Resilience), and Manu Lecomte.
The round follows Lucis’s $8 million seed raised four months ago, bringing total funding to $28 million.
Lucis said the latest capital will support expansion across Europe and continued development of its AI-driven health companion app. The raise comes as demand for proactive, data-driven health services continues to grow.
Since launching in 2025, Lucis has expanded to more than 10,000 users across France, the UK, Ireland, and Portugal, and has delivered over one million biomarker tests. The startup has also built a community of thousands of members and established partnerships with laboratory groups, including Eurofins and Randox.
Lucis plans to expand into Spain, Germany, and Italy by the end of 2026, while continuing to invest in personalisation, longitudinal monitoring, and clinical safety.
The Lucis app provides individuals with a comprehensive, data-driven view of their health. The app analyses more than 110 blood biomarkers across key systems, including metabolic health, hormones, cardiovascular risk, inflammation, and nutrient levels.
Lucis combines AI with clinical oversight to deliver continuous, individualized guidance. Its app-based platform brings together biomarker data, medical context, longitudinal health data, and validated clinical protocols to help users track changes in their health and take action over time.
Digital health companies, including personalised care startups, have secured more than $180 billion in funding to date, according to our recent Funding Database. More recently, Nourish Inc, a dietitian-led virtual metabolic care startup, raised $100 million in Series C funding.
In another deal, Dehaze, a Germany–based healthtech startup developing a foundational AI model for chronic disease detection, raised €3.2 million in a Seed funding round.